Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.Listen as he gives his perspectives on:Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TCThe SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patientsReal-world experience with switching to DTG/RPV from the OPERA studyThe TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimenThe SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimenPresenter:William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaFollow along with the slides at:https://bit.ly/3n0Z8wUSee the entire program at:https://bit.ly/2TXTYWx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

There are no comments yet.

Please log in to write the first comment.